Rotavirus Vaccine — A Powerful Tool to Combat Deaths from Diarrhea
Author:
- Mathuram SantoshamMSMathuram Santosham
Open Access
- 28 January 2010
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 362 (4) , 358-360
Abstract
Rotavirus infection, the leading cause of severe childhood diarrhea in both developed and developing countries, results in over half a million deaths each year.1 Currently, two rotavirus vaccines (Rotarix [GlaxoSmithKline Biologicals] and RotaTeq [Merck]) are licensed in many countries and used routinely in several. Until recently, available efficacy data were from developed and developing countries with relatively low mortality rates among children younger than 5 years of age.Keywords
This publication has 8 references indexed in Scilit:
- Vaccine-Acquired Rotavirus in Infants with Severe Combined ImmunodeficiencyNew England Journal of Medicine, 2010
- Effect of Rotavirus Vaccination on Death from Childhood Diarrhea in MexicoNew England Journal of Medicine, 2010
- Effect of Human Rotavirus Vaccine on Severe Diarrhea in African InfantsNew England Journal of Medicine, 2010
- Rotavirus Vaccination: Cost‐Effectiveness and Impact on Child Mortality in Developing CountriesThe Journal of Infectious Diseases, 2009
- Global Mortality Associated with Rotavirus Disease among Children in 2004The Journal of Infectious Diseases, 2009
- Timing of children's vaccinations in 45 low-income and middle-income countries: an analysis of survey dataThe Lancet, 2009
- Safety and Efficacy of a Pentavalent Human–Bovine (WC3) Reassortant Rotavirus VaccineNew England Journal of Medicine, 2006
- Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus GastroenteritisNew England Journal of Medicine, 2006